Area of research
Cardiology and Cardiovascular Medicine · Complementary and alternative medicine
Research interest
Research interests include Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Cardiac pacing and defibrillation studies, and Cardiovascular and exercise physiology.
Standardized Definitions of Changes in Kidney Function in Trials of Heart Failure
Artificial Intelligence in Cardiovascular Clinical Trials
Effect of Vericiguat on Left Ventricular Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction: The VICTORIA Echocardiographic Substudy
Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies
Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA
Abstract 12936: Quality of Life Assessments as Inclusion Criteria in Heart Failure Clinical Trials
Interventions for Frailty Among Older Adults With Cardiovascular Disease
Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials
Functional and Symptomatic Clinical Trial Endpoints
Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum
Sequential Evaluation of NT-proBNP in Heart Failure
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> ( <scp>Vericiguat</scp> Global Study in Subjects with <scp>HFrEF</scp> ) trial
Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> trial
Participation in a Heart Failure Clinical Trial
Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium
Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials
Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event
Treatment with 24 Hour Istaroxime Infusion in Patients Hospitalised for Acute Heart Failure: A Randomised, Placebo-Controlled Trial
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium
Sarcopenia and health-related quality of life in older adults after transcatheter aortic valve replacement
Impact of Exercise Rehabilitation on Exercise Capacity and Quality-of-Life in Heart Failure
The Hospital Readmissions Reduction Program
Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) Trial